Steven Caras
Overview
Explore the profile of Steven Caras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caras S, Sharpe T
J Child Adolesc Psychopharmacol
. 2019 Dec;
30(2):69-80.
PMID: 31809216
We evaluated the pharmacokinetics (PK) of an investigational immediate-release amphetamine (AMP) sulfate formulation (AR19) designed to deter nonoral administration versus reference racemic amphetamine sulfate (RA-AMPH). We investigated AMP bioavailability from...
2.
Falk D, Ryan M, Fertig J, Devine E, Cruz R, Brown E, et al.
Alcohol Clin Exp Res
. 2018 Nov;
43(1):158-169.
PMID: 30403402
Background: Several single-site alcohol treatment clinical trials have demonstrated efficacy for immediate-release (IR) gabapentin in reducing drinking outcomes among individuals with alcohol dependence. The purpose of this study was to...
3.
Shlieout G, Koerner A, Maffert M, Forssmann K, Caras S
Clin Drug Investig
. 2011 Jun;
31(7):e1-7.
PMID: 21627335
Background And Objectives: In clinical practice, the need sometimes arises to administer pancreatic enzyme replacement therapy via gastrostomy tube (G-tube) by mixing the pellets contained in the capsules with soft...
4.
CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency
Kuhn R, Gelrud A, Munck A, Caras S
Adv Ther
. 2010 Nov;
27(12):895-916.
PMID: 21086085
Exocrine pancreatic insufficiency (EPI) is associated with conditions including cystic fibrosis (CF), chronic pancreatitis (CP), and pancreatic surgery (PS). The symptoms include maldigestion, malnutrition, weight loss, flatulence, and steatorrhea. Pancreatic...
5.
Whitcomb D, Lehman G, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al.
Am J Gastroenterol
. 2010 May;
105(10):2276-86.
PMID: 20502447
Objectives: Pancreatic-enzyme replacement therapy (PERT) is the standard of care to prevent maldigestion, malnutrition, and excessive weight loss in patients with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP)...
6.
Graff G, McNamara J, Royall J, Caras S, Forssmann K
Clin Drug Investig
. 2010 May;
30(6):351-64.
PMID: 20441244
Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive enzymes caused by diseases such as cystic fibrosis (CF). Patients with EPI due to CF require pancreatic enzyme replacement therapy (PERT)...
7.
Trapnell B, Maguiness K, Graff G, Boyd D, Beckmann K, Caras S
J Cyst Fibros
. 2009 Oct;
8(6):370-7.
PMID: 19815466
Background: Pancreatic enzyme replacement therapy is critical for adequate nutrition in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). Methods: This was a double-blind, randomised, placebo-controlled, two-period crossover study...